Skip to content

Prospective placebo-controlled study of bifidobacterium in improving acute diarrhea in infants

Prospective placebo-controlled study of bifidobacterium in improving acute diarrhea in infants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094620
Enrollment
Unknown
Registered
2024-12-25
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infant acute diarrhea

Interventions

Acute diarrhea-Control:Take placebo
Acute diarrhea-CCFM1078:Take CCFM1078
Acute diarrhea-CCFM1269:Take CCFM1269

Sponsors

Department of Gastroenterology, Children's Hospital of Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 3 Years

Inclusion criteria

Inclusion criteria: (1)Age 0-3 years old, gender unlimited; (2) Meet the diagnosis of acute diarrhea: defecation 3 or more times a day, the duration of not more than 2 weeks, increased frequency of stool or changes in stool characteristics in the past 24 hours, may be accompanied by nausea, vomiting, abdominal pain or fever and other systemic symptoms; Bristol type 6-7. (3) The patient's family members have good communication skills and can follow the requirements of the study protocol to complete the records and follow-up. The patient's family members signed informed consent and were willing to participate in the clinical trial.

Exclusion criteria

Exclusion criteria: (1) Chronic and prolonged diarrhea; (2) Allergic or adverse reactions to bifidobacterium brevis CCFM1078 and Bifidobacterium longum CCFM1269 and similar drugs; (3) There are serious metabolic diseases, serious chronic cardiovascular and cerebrovascular, lung, liver, kidney and other chronic diseases, combined with disease medication may affect gastrointestinal motility. (4) organic gastrointestinal diseases (inflammatory bowel diseases, tumors, etc.); (5) Long-term abuse of laxatives or systemic corticosteroids; (6) The guardian of the subject refuses to sign the informed consent, and the follow-up compliance is poor; (7) Participants in clinical trials of other investigational drugs in the past 12 weeks; Use antimicrobials, probiotics, laxatives, and other medications that may affect bowel movements within 4 weeks before the start of the study.

Design outcomes

Primary

MeasureTime frame
Fecal 16S rDNA sequence;Short chain fatty acids;Inflammatory factors;Neurotransmitters;Immunoglobulin;

Secondary

MeasureTime frame
Stool routine examination;Blood routine examination;Blood biochemical;Faecal calprotectin;urine routine examination;

Countries

China

Contacts

Public ContactZhang Ting

Department of Gastroenterology, Children's Hospital of Shanghai

zhangt@shchildren.com.cn+86 180 1648 7615

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026